A price for cost-effectiveness: implications for recombinant human activated protein C (rhAPC)
- PMID: 12545034
- DOI: 10.1097/00003246-200301000-00049
A price for cost-effectiveness: implications for recombinant human activated protein C (rhAPC)
Comment on
-
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.Crit Care Med. 2003 Jan;31(1):1-11. doi: 10.1097/00003246-200301000-00001. Crit Care Med. 2003. PMID: 12544986 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical